{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:25:47Z","timestamp":1786998347882,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.ygyno.2017.05.011","type":"journal-article","created":{"date-parts":[[2017,5,20]],"date-time":"2017-05-20T10:00:16Z","timestamp":1495274416000},"page":"305-313","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Identification of molecular targets in vulvar cancers"],"prefix":"10.1016","volume":"146","author":[{"given":"Marguerite L.","family":"Palisoul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary M.","family":"Mullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0568-6959","authenticated-orcid":false,"given":"Premal H.","family":"Thaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2017.05.011_bb0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics","volume":"67","author":"Siegel","year":"2017","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2017.05.011_bb0010","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40661-015-0018-x","article-title":"Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience","volume":"2","author":"Fu","year":"2015","journal-title":"Gynecol. Oncol. Res. Pract."},{"issue":"1","key":"10.1016\/j.ygyno.2017.05.011_bb0015","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/his.12034","article-title":"Pathways of vulvar intraepithelial neoplasia and squamous cell carcinoma","volume":"62","author":"Del Pino","year":"2013","journal-title":"Histopathology"},{"issue":"8","key":"10.1016\/j.ygyno.2017.05.011_bb0020","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1097\/PAS.0000000000000454","article-title":"Squamous cell carcinoma of the vulva: a subclassification of 97 cases by clinicopathologic, immunohistochemical, and molecular features (p16, p53, and EGFR)","volume":"39","author":"Dong","year":"2015","journal-title":"Am. J. Surg. Pathol."},{"issue":"3","key":"10.1016\/j.ygyno.2017.05.011_bb0025","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF02893362","article-title":"Immunohistochemical expression of p16 and p53 in vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva","volume":"12","author":"Nogueira","year":"2006","journal-title":"Pathol. Oncol. Res."},{"issue":"5","key":"10.1016\/j.ygyno.2017.05.011_bb0030","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1133::AID-CNCR17>3.0.CO;2-T","article-title":"p53 protein expression in squamous cell carcinoma of the vulva","volume":"85","author":"Scheistroen","year":"1999","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.ygyno.2017.05.011_bb0035","first-page":"3228","article-title":"Somatic mutation of PTEN in vulvar cancer","volume":"6","author":"Holway","year":"2000","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.ygyno.2017.05.011_bb0040","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ygyno.2008.07.038","article-title":"Decreased survival in EGFR gene amplified vulvar carcinoma","volume":"111","author":"Growdon","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.011_bb0045","series-title":"Blaustein's Pathology of the Female Genital Tract","author":"K","year":"2002"},{"key":"10.1016\/j.ygyno.2017.05.011_bb0050","series-title":"National Comprehensive Cancer Network: Vulvar Cancer","author":"NCCN","year":"2016"},{"issue":"2","key":"10.1016\/j.ygyno.2017.05.011_bb0055","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/00000421-198904000-00011","article-title":"Mitoxantrone in the treatment of advanced vulvar and vaginal carcinoma. A gynecologic oncology group study","volume":"12","author":"Muss","year":"1989","journal-title":"Am. J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2017.05.011_bb0060","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/0090-8258(86)90138-1","article-title":"Phase II trials of cisplatin and piperazinedione in advanced or recurrent squamous cell carcinoma of the vulva: a Gynecologic Oncology Group Study","volume":"23","author":"Thigpen","year":"1986","journal-title":"Gynecol. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2017.05.011_bb0065","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/annonc\/mdp043","article-title":"Phase II study on paclitaxel in patients with recurrent, metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTC-GCG (European Organisation for Research and Treatment of Cancer\u2014Gynaecological Cancer Group)","volume":"20","author":"Witteveen","year":"2009","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2017.05.011_bb0070","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/annonc\/mdw226","article-title":"The promise of immunotherapy in head and neck squamous cell carcinoma","volume":"27","author":"Economopoulou","year":"2016","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2017.05.011_bb0075","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2017.05.011_bb0080","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","article-title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival","volume":"11","author":"Bonner","year":"2010","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2017.05.011_bb0085","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1093\/annonc\/mdw242","article-title":"The forgotten woman's cancer: vulvar squamous cell carcinoma (VSCC) and a targeted approach to therapy","volume":"27","author":"Clancy","year":"2016","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2017.05.011_bb0090","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ygyno.2006.07.035","article-title":"EGFR expression is associated with groin node metastases in vulvar cancer, but does not improve their prediction","volume":"104","author":"Oonk","year":"2007","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2017.05.011_bb0095","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/pgp.0b013e3180555999","article-title":"Epidermal growth factor receptor is involved in the development of an invasive phenotype in vulvar squamous lesions, but is not related to MIB-1 immunoreactivity","volume":"26","author":"Brustmann","year":"2007","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"3","key":"10.1016\/j.ygyno.2017.05.011_bb0100","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1006\/gyno.1997.4660","article-title":"Epidermal growth factor receptor in vulvar malignancies and its relationship to metastasis and patient survival","volume":"65","author":"Johnson","year":"1997","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2017.05.011_bb0105","doi-asserted-by":"crossref","first-page":"170","DOI":"10.2174\/1574892811666160309121238","article-title":"Anti-EGFR therapy: strategies in head and neck squamous cell carcinoma","volume":"11","author":"Oliveira-Silva","year":"2016","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"10.1016\/j.ygyno.2017.05.011_bb0110","first-page":"1","article-title":"Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancer","author":"Sunakawa","year":"2016","journal-title":"Cancer Biol. Ther."},{"issue":"1","key":"10.1016\/j.ygyno.2017.05.011_bb0115","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ygyno.2012.06.028","article-title":"Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva","volume":"127","author":"Horowitz","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2017.05.011_bb0120","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1080\/15216540701736285","article-title":"Role of the MRP1\/ABCC1 multidrug transporter protein in cancer","volume":"59","author":"Munoz","year":"2007","journal-title":"IUBMB Life"},{"issue":"7","key":"10.1016\/j.ygyno.2017.05.011_bb0125","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1200\/JCO.2009.27.5644","article-title":"Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy","volume":"29","author":"Press","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.011_bb0130","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev.bi.62.070193.002125","article-title":"Biochemistry of multidrug resistance mediated by the multidrug transporter","volume":"62","author":"Gottesman","year":"1993","journal-title":"Annu. Rev. Biochem."},{"issue":"2","key":"10.1016\/j.ygyno.2017.05.011_bb0135","doi-asserted-by":"crossref","first-page":"R17","DOI":"10.1186\/bcr2241","article-title":"TLE3 as a candidate biomarker of response to taxane therapy","volume":"11","author":"Kulkarni","year":"2009","journal-title":"Breast Cancer Res."},{"issue":"2","key":"10.1016\/j.ygyno.2017.05.011_bb0140","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/107327480301000207","article-title":"Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein","volume":"10","author":"Thomas","year":"2003","journal-title":"Cancer Control"},{"issue":"15","key":"10.1016\/j.ygyno.2017.05.011_bb0145","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1158\/1078-0432.CCR-11-0658","article-title":"Class III beta-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial","volume":"17","author":"Vilmar","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.ygyno.2017.05.011_bb0150","first-page":"4842","article-title":"Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation","volume":"61","author":"Moynahan","year":"2001","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.ygyno.2017.05.011_bb0155","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1002\/ijc.23822","article-title":"Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine-based chemotherapy: evidence from 24 studies","volume":"123","author":"Qiu","year":"2008","journal-title":"Int. J. Cancer"},{"issue":"9","key":"10.1016\/j.ygyno.2017.05.011_bb0160","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1093\/annonc\/mdq053","article-title":"ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial","volume":"21","author":"Vilmar","year":"2010","journal-title":"Ann. Oncol."},{"issue":"7528","key":"10.1016\/j.ygyno.2017.05.011_bb0165","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"issue":"26","key":"10.1016\/j.ygyno.2017.05.011_bb0170","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ygyno.2017.05.011_bb0175","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1158\/1535-7163.MCT-14-0735-T","article-title":"Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence","volume":"14","author":"Osman","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"9","key":"10.1016\/j.ygyno.2017.05.011_bb0180","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1001\/archoto.2009.122","article-title":"A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: report of the Southwest Oncology Group","volume":"135","author":"Yoo","year":"2009","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"issue":"10","key":"10.1016\/j.ygyno.2017.05.011_bb0185","first-page":"927","article-title":"Multidrug resistance-associated protein 1 (MRP1\/ABCC1) polymorphism: from discovery to clinical application","volume":"36","author":"Yin","year":"2011","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"issue":"2","key":"10.1016\/j.ygyno.2017.05.011_bb0190","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1158\/0008-5472.CAN-14-2740","article-title":"TUBB3\/betaIII-tubulin acts through the PTEN\/AKT signaling axis to promote tumorigenesis and anoikis resistance in non-small cell lung cancer","volume":"75","author":"McCarroll","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2017.05.011_bb0195","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1038\/srep04313","article-title":"Measuring ERCC1 protein expression in cancer specimens: validation of a novel antibody","volume":"4","author":"Smith","year":"2014","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.ygyno.2017.05.011_bb0200","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa065411","article-title":"DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer","volume":"356","author":"Zheng","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ygyno.2017.05.011_bb0205","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1136\/gut.2004.059535","article-title":"O(6)-methylguanine methyltransferase in colorectal cancers: detection of mutations, loss of expression, and weak association with G:C>A:T transitions","volume":"54","author":"Halford","year":"2005","journal-title":"Gut"},{"issue":"2\u20133","key":"10.1016\/j.ygyno.2017.05.011_bb0210","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0925-4439(02)00082-0","article-title":"Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism","volume":"1587","author":"Peters","year":"2002","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/j.ygyno.2017.05.011_bb0215","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0304-3835(95)03915-J","article-title":"Selective tumorigenesis in non-parenchymal liver epithelial cell lines by hepatocyte growth factor transfection","volume":"96","author":"Johnson","year":"1995","journal-title":"Cancer Lett."},{"issue":"21","key":"10.1016\/j.ygyno.2017.05.011_bb0220","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1002\/cncr.28288","article-title":"Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix","volume":"119","author":"Wright","year":"2013","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.ygyno.2017.05.011_bb0225","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/2159-8290.CD-13-0310","article-title":"Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors","volume":"3","author":"Akbay","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ygyno.2017.05.011_bb0230","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4103\/1477-3163.44372","article-title":"Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer","volume":"7","author":"Puri","year":"2008","journal-title":"J. Carcinog."},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2017.05.011_bb0235","doi-asserted-by":"crossref","first-page":"E1625","DOI":"10.1002\/hed.24290","article-title":"Molecular profiling of head and neck squamous cell carcinoma","volume":"38","author":"Feldman","year":"2016","journal-title":"Head Neck"},{"issue":"1","key":"10.1016\/j.ygyno.2017.05.011_bb0240","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/cncr.10206","article-title":"The prognostic value of immunohistochemically detected CD44v3 and CD44v6 expression in patients with surgically staged vulvar carcinoma: a multicenter study","volume":"94","author":"Hefler","year":"2002","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2017.05.011_bb0245","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ygyno.2004.07.026","article-title":"p16INK4a and p21Waf1\/Cip1 expression correlates with clinical outcome in vulvar carcinomas","volume":"95","author":"Knopp","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2017.05.011_bb0250","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1006\/gyno.1996.0307","article-title":"Influence of microvessel density and vascular permeability factor\/vascular endothelial growth factor expression on prognosis in vulvar cancer","volume":"63","author":"Obermair","year":"1996","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817308508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817308508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T12:27:13Z","timestamp":1535804833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825817308508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0090825817308508"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.05.011","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of molecular targets in vulvar cancers","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}